Results 91 to 100 of about 1,815 (184)

Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice [PDF]

Endocrinology, 2015
Abstract Sodium glucose cotransporter 2 inhibitors have attracted attention as they exert antidiabetic and antiobesity effects. In this study, we investigated the effects of tofogliflozin on glucose homeostasis and its metabolic consequences and clarified the underlying molecular mechanisms.
Atsushi, Obata, Naoto, Kubota, Tetsuya, Kubota, Masahiko, Iwamoto, Hiroyuki, Sato, Yoshitaka, Sakurai, Iseki, Takamoto, Hisayuki, Katsuyama, Yoshiyuki, Suzuki, Masanori, Fukazawa, Sachiya, Ikeda, Kaito, Iwayama, Kumpei, Tokuyama, Kohjiro, Ueki, Takashi, Kadowaki   +14 more
openaire   +2 more sources

Effect of SGLT2 inhibitors on liver fat content: A meta-analysis. [PDF]

Biomol Biomed
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major metabolic disorder linked to increased morbidity and mortality. Sodium-glucose co-transporter-2 (SGLT2) inhibitors, commonly used to manage type 2 diabetes (T2DM), have shown ...
Ge Q, Zhang F, Liu Y.
europepmc   +3 more sources

Albuminuria and Serum Tumor Necrosis Factor Receptor Levels in Patients with Type 2 Diabetes on SGLT2 Inhibitors : A Prospective Study [PDF]

, 2023
Introduction: Large-scale clinical trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i) demonstrate proteinuria-reducing effects in diabetic kidney disease, even after treatment with renin–angiotensin inhibitors.
10948/profile-ja.html, 1115, 1224, 1488, 168, 205776/profile-ja.html, 385041/profile-ja.html, 415, 50304556, 60362737, 60594/profile-ja.html, 60624400, 70372711, 725, 75205/profile-ja.html, 80179879, Aihara, Ken-ichi, Hara, Tomoyo, Matsuhisa, Munehide, Otoda, Toshiki, Sekine, Akiko, Tamaki, Motoyuki, Tamaki, Toshiaki, Tsuji, Seijiro, Uemoto, Ryoko, Yuasa, Tomoyuki, アイハラ, ケンイチ, ウエモト, リョウコ, ウエモト, リョウコ, オトダ, トシキ, セキネ, アキコ, セキネ, アキコ, タマキ, トシアキ, タマキ, モトユキ, ツジ, セイジロウ, ツジ, セイジロウ, ハラ, トモヨ, マツヒサ, ムネヒデ, ユアサ, トモユキ, 乙田, 敏城, 原, 倫世, 松久, 宗英, 湯浅, 智之, 玉置, 俊晃, 田蒔, 基行, 粟飯原, 賢一   +45 more
core  

The influence of sodium-glucose co-transporter-2 inhibitors on the risk of cancer therapy-related cardiac dysfunction: A meta-analysis. [PDF]

Biomol Biomed
Cancer therapy-related cardiac dysfunction (CTRCD) is a major concern for patients undergoing cardiotoxic cancer treatments. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown cardioprotective effects in both diabetic and non-diabetic ...
Yan Z, Xing X, Huang J.
europepmc   +3 more sources

Effects of the Sodium‐Glucose Cotransporter‐2 Inhibitor Velagliflozin on Insulin Concentrations in Horses With Insulin Dysregulation

Journal of Veterinary Internal Medicine, Volume 39, Issue 6, November/December 2025.
ABSTRACT Background Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are promising treatments to manage hyperinsulinemia in horses with insulin dysregulation (ID). Hypothesis The SGLT2i velagliflozin decreases insulin concentration in horses with ID. Animals Privately‐owned adult horses (n = 37) with laboratory‐confirmed ID (low‐dose oral sugar test ...
Kristen Thane, Rebecca Voth, Rebecca Klee, Tobias Warnken, Victor Chukwu, Nicholas Frank   +5 more
wiley   +1 more source

Gender Differences in Cardiac Function Following Three-Month Administration of Tofogliflozin in Patients With Diabetes Mellitus

Journal of Clinical Medicine Research, 2020
Patients with type 2 diabetes mellitus (T2DM) are at increased risk for impairment in heart failure and diastolic relaxation while preserving ejection fraction (EF). Recently, several sodium glucose cotransporter-2 (SGLT2) inhibitors have demonstrated to decrease cardiovascular disease (CVD) events in elderly diabetic patients, although gender ...
Higashikawa, Toshihiro, Ito, Tomohiko, Mizuno, Takurou, Ishigami, Keiichiro, Kohori, Masaru, Mae, Kunihiro, Usuda, Daisuke, Takeshima, Kento, Takagi, Susumu, Izumida, Toshihide, Yamada, Shinya, Kuroki, Kengo, Sangen, Ryusho, Saito, Atsushi, Iguchi, Masaharu, Kamasaki, Yuji, Nakahashi, Takeshi, Fukuda, Akihiro, Kanda, Tsugiyasu, Okuro, Masashi   +19 more
openaire   +3 more sources

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3):a multinational observational cohort study [PDF]

, 2020
Background: Cardiovascular and kidney outcome trials have shown that sodium-glucose co-transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with type 2 diabetes with or without chronic kidney disease.
Cea-Soriano, Lucia, Chodick, Gabriel, Fenici, Peter, Garcia Rodriguez, Luis Alberto, Heerspink, Hiddo J.L., Karasik, Avraham, Khunti, Kamlesh, Kohsaka, Shun, Kosiborod, Mikhail, Lin, Fang Ju, Lucisano, Giuseppe, Melzer-Cohen, Cheli, Nicolucci, Antonio, Thuresson, Marcus, Wang, Chih Yuan, Wilding, John P.H., Wittbrodt, Eric   +16 more
core   +1 more source

Expanding the Chemical Space of Sugar Frameworks by Quaternization of the Anomeric Carbon Atom

European Journal of Organic Chemistry, Volume 28, Issue 37, October 11, 2025.
Novel C,C and C,N bifunctional fucosides are stereoselectively obtained starting from a common anomeric bromide intermediate. The developed methodology expands the chemical space at the anomeric position of fucose and supports future applications in glycomimetics design.
Sarah Mazzotta, Jacopo Gori, Gianluca Cavazzoli, Sara Sattin, Giovanni Macetti, Anna Bernardi   +5 more
wiley   +1 more source

Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan

Diabetes, Obesity and Metabolism, Volume 27, Issue 7, Page 3714-3724, July 2025.
Abstract Aims To describe temporal changes in the characteristics of medication‐initiator cohorts in persons with chronic kidney disease (CKD) and type 2 diabetes (T2D). Materials and Methods Adults with CKD and T2D initiating sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) or glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) were identified in ...
Yuichiro Yano, Suguru Okami, Hiroshi Kanegae, Nikolaus G. Oberprieler, Catherine Johannes, Satoshi Yamashita, Kanae Yoshikawa‐Ryan, Csaba P. Kovesdy, David Vizcaya, Naoki Kashihara   +9 more
wiley   +1 more source

Multivariate generalized mixed-effects models for screening multiple adverse drug reactions in spontaneous reporting systems [PDF]

journal ...
Gosho Masahiko, Ishii Ryota, Maruo Kazushi, Ohigashi Tomohiro   +3 more
core   +1 more source